BioTime, Inc. (NYSEAMERICAN:BTX) was down 5.3% on Friday . The company traded as low as $2.50 and last traded at $2.50. Approximately 568,135 shares were traded during mid-day trading, an increase of 10% from the average daily volume of 514,273 shares. The stock had previously closed at $2.64.
A number of equities research analysts have weighed in on BTX shares. Lake Street Capital started coverage on shares of BioTime in a report on Friday, February 2nd. They issued a “buy” rating and a $8.00 price target for the company. Zacks Investment Research downgraded shares of BioTime from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Three analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.81.
The firm has a market capitalization of $338.75, a P/E ratio of 5.81 and a beta of 1.96.
TRADEMARK VIOLATION NOTICE: “BioTime (BTX) Trading Down 5.3%” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3299167/biotime-btx-trading-down-5-3.html.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.